Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 667920

Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?


Badžek, Saša; Kelović Lesko, Vesna; Pleština, Stjepko; Humar, Ines; Veir, Zoran; Mihaljević, Zoran
Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off? // Wiener klinische Wochenschrift, 123 (2011), 23/24; 726-731 doi:10.1007/s00508-011-0099-4 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 667920 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?

Autori
Badžek, Saša ; Kelović Lesko, Vesna ; Pleština, Stjepko ; Humar, Ines ; Veir, Zoran ; Mihaljević, Zoran

Izvornik
Wiener klinische Wochenschrift (0043-5325) 123 (2011), 23/24; 726-731

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
breast cancer; HER2/ECD; tumor markers

Sažetak
HER2 overexpression is well- established risk factor of worse prognosis in metastatic and early breast cancer. HER2 positivity can be determined from tumor tissue by immunohistochemical staining or by fluorescent in situ hybridization, or from serum by measuring concentration of HER2 receptor extracellular domain (HER2/ECD). HER2/ECD correlates well with worse prognosis in metastatic and locally advanced (stage III) disease if serum concentration is >15 ng/ml, but there are no consistent data for patients with early breast cancer. 41 patients with stage I and II breast cancer and 52 healthy controls were included into the study. HER2/ECD was determined before surgery and correlated with HER2/neu overexpression, Ki67, hormone receptor status and disease stage, and compared with value in healthy controls. Mean serum HER2/ECD concentration in patients was 8.62 ng/ml and 5.78 ng/ml in controls, and the difference was statistically significant (p = 0.000061). The best diagnostic cut-off value was 7.7 ng/ml, with 76.92% sensitivity and 72.92% specificity. Positive predictive value of the test was 69.77% and negative predictive value was 79.55%, with 74.71% of patients correctly classified. Serum HER2/ECD correlated with hormone receptors status, and no correlation with histological overexpression has been observed. Serum HER2/ECD concentration of ≥7.7 ng/ml has possible diagnostic value in stage I and II breast cancer. It should not be used as a determinant of HER2 positivity. Prognostic significance of HER2/ECD in early breast cancer, its correlation with hormone receptor status, and interconnection between hormone receptors and HER2 receptor signaling should be further analyzed, since it may have therapeutic implications.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Projekti:
108-1080058-0047 - Molekularni biljezi u solidnim tumorima - prediktivni i prognostički značaj (Pleština, Stjepko, MZOS ) ( CroRIS)

Ustanove:
Hrvatski veterinarski institut, Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Profili:

Avatar Url Stjepko Pleština (autor)

Avatar Url Zoran Veir (autor)

Avatar Url Ines Humar (autor)

Avatar Url Saša Badžek (autor)

Poveznice na cjeloviti tekst rada:

doi link.springer.com

Citiraj ovu publikaciju:

Badžek, Saša; Kelović Lesko, Vesna; Pleština, Stjepko; Humar, Ines; Veir, Zoran; Mihaljević, Zoran
Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off? // Wiener klinische Wochenschrift, 123 (2011), 23/24; 726-731 doi:10.1007/s00508-011-0099-4 (međunarodna recenzija, članak, znanstveni)
Badžek, S., Kelović Lesko, V., Pleština, S., Humar, I., Veir, Z. & Mihaljević, Z. (2011) Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?. Wiener klinische Wochenschrift, 123 (23/24), 726-731 doi:10.1007/s00508-011-0099-4.
@article{article, author = {Bad\v{z}ek, Sa\v{s}a and Kelovi\'{c} Lesko, Vesna and Ple\v{s}tina, Stjepko and Humar, Ines and Veir, Zoran and Mihaljevi\'{c}, Zoran}, year = {2011}, pages = {726-731}, DOI = {10.1007/s00508-011-0099-4}, keywords = {breast cancer, HER2/ECD, tumor markers}, journal = {Wiener klinische Wochenschrift}, doi = {10.1007/s00508-011-0099-4}, volume = {123}, number = {23/24}, issn = {0043-5325}, title = {Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?}, keyword = {breast cancer, HER2/ECD, tumor markers} }
@article{article, author = {Bad\v{z}ek, Sa\v{s}a and Kelovi\'{c} Lesko, Vesna and Ple\v{s}tina, Stjepko and Humar, Ines and Veir, Zoran and Mihaljevi\'{c}, Zoran}, year = {2011}, pages = {726-731}, DOI = {10.1007/s00508-011-0099-4}, keywords = {breast cancer, HER2/ECD, tumor markers}, journal = {Wiener klinische Wochenschrift}, doi = {10.1007/s00508-011-0099-4}, volume = {123}, number = {23/24}, issn = {0043-5325}, title = {Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?}, keyword = {breast cancer, HER2/ECD, tumor markers} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font